Incannex Healthcare, Inc. (IXHL) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$2.85

From 52W high−80.78%

Volume68148.00

Market cap$34.62M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$2.85

From 52W high

−80.78%

Volume

68148.00

Market cap

$34.62M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.4x

P/E (TTM)

—

RSI (14)

31.2

MomentumView details →

1D Return

−2.13%

YTD Return

−73.84%

SummaryUpdated Jun 1, 2026

Incannex Healthcare Limited (ASX:IXHL) is an Australian pharmaceutical company that develops medicinal cannabinoid products for various medical conditions. Founded in 2001 and originally known as Impression Healthcare Limited, the company rebranded to Incannex Healthcare in June 2020 to reflect its focus on cannabinoid-based therapeutics. The company went public on the Australian Securities Exchange in March 2022. Incannex is currently in the clinical development phase, with multiple drug candidates in various stages of trials targeting conditions such as obstructive sleep apnea, traumatic brain injury, and inflammatory diseases.

Ask drillr about Incannex Healthcare, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−28.65%

ROA (TTM)

−26.45%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+95.93%

EBITDA YoY

—

MomentumView details →

1D Return

−2.13%

YTD Return

−73.84%

1Y Return

−75.35%

RSI (14)

31.2

vs 50D SMA

−14.94%

vs 200D SMA

−39.07%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

48.81x

Quick Ratio

48.81x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.14

EPS Surprise

−207.69%

Beats (12Q)

2/12

Next Q EPS Est

−$0.54

Avg Surprise (4Q)

−37.96%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

66616.00

Net Income (TTM)

−52.32M

Op. CF (TTM)

—

Next earningsNov 13, 2026 →

Latest newsMore news →

Incannex Healthcare commenced patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea.41d ago

Incannex Healthcare was granted a U.S. composition and methods of treatment patent covering IHL-42X with baseline expiry in 2040.41d ago

Similar companies

Cosmos Health Inc.COSM SCYNEXIS, Inc.SCYX Rockwell Medical, Inc.RMTI Zhengye Biotechnology Holding LimitedZYBT Shuttle Pharmaceuticals Holdings, Inc.SHPH TherapeuticsMD, Inc.TXMD Find similar companies →

Latest newsMore news →

Incannex Healthcare commenced patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea.41d ago Incannex Healthcare was granted a U.S. composition and methods of treatment patent covering IHL-42X with baseline expiry in 2040.41d ago